|
Acomplia Shows 'Modest' Weight Loss
Oct. 17, 2006 -- The weight loss drug Acomplia hasn't been approved by the FDA, but it's already drawing attention from the public and scientists. The latest Acomplia headlines appear online in The Cochrane Library. The researchers included graduate student Cintia Curioni, MSc, of Brazil's University of Rio de Janeiro. They reviewed four studies on Acomplia's use in more than 6,600 overweight and obese adults. For one or two years, participants either took Acomplia in higher or lower doses (20 milligrams or 5 milligrams daily) or pills containing no medicine (placebo). But they didn't just pop pills. They also shaved about 600 calories off their daily diet. Pounds Shed, Waists Slimmed The studies' key question: Who lost the most weight? The answer: Participants taking the higher dose of Acomplia.
LipoFemme Sets the New Standard for Women's Weight Loss ...
The women's weight loss market has been flooded with gimmick after gimmick for the last ten years. Gimmicks such as topical fat-loss creams, pricey diet programs, and useless ab gadgets - scams that don't work. There is now a solution to weight loss that delivers more than lost pounds. Lipofemme, A newly developed diet pill has been found to increase anti-aging and beautifying components in the body, as well as reduce body fat twice as effectively than diet pills of the past. (PRWEB) November 1, 2006 -- The advancements made in the supplement industry have been constant and increasing for quite some time. PHR Laboratories has furthered those advancements by creating a new beautifying and health-supporting weight loss pill. Given all of the hype and promotion surrounding diet pills, one would be surprised to learn that this is, in fact, a well developed weight loss supplement that can support real progress for women trying to lose weight.
Merck Abandons a Diet Pill, But Trials of a Diet Drug Similar to ...
For the second time this year, Merck & Company has abandoned a once-thought-promising weight loss drug in the face of discouraging trial results. But a large phase II trial continues on a more encouraging note of Merck's drug believed similar to Sanofi's diet pill Acomplia (rimonabant). The latest Merck drug to bite the dust is MK-0557, which turns out to have been a Neuropeptide Y5 receptor (NPY5R) antagonist which entered the brain and bound tightly to a protein that it was designed to inhibit: an appetite-stimulating molecule called neuropeptide Y. Merck early on had high hopes for this drug. Rodent trials showed that mice ate less when given MK-0557 and human patients in a phase I trial experienced no severe side effects. But in a year-long multicenter phase II trial involving 1,661 overweight and obese patients, who either received a 1 mg daily dose of MK-0557 or a placebo in addition to following a diet and exercise program, those on the Merck pill lost on average less than 3 pounds more than those on the placebo.
Sanofi Denies FDA Asking for Acomplia Safety Data From Diet Drug ...
While Sanofi-Aventis is busily gathering data on patient use of diet drug Acomplia in Europe to track side effects that may emerge during its initial months of sale, the company denied Oct. 6 that FDA has asked for more safety data as it weighs approving the diet pill for sale in the United States. Doug Greene, Sanofi's chief medical officer, provided the strongest hint to date that FDA -- where Acomplia has been on hold for seven months -- remains concerned about possible safety issues associated with a novel weight-loss drug that acts on receptors in the brain. In clinical trials, psychiatric side effects such as anxiety or depression accounted for about half of all drop outs attributed to adverse experiences with the 20 mg dose of rimonabant -- the higher trial dose that is now being prescribed to patients in Europe.
|
